Axovant Sciences (NYSE: AXON), Esperion Therapeutics (NASDAQ: ESPR), and Aerie Pharmaceuticals (NASDAQ: AERI) have late-stage drugs in development that could catapult them to profitability in the next few years. Will they overcome the odds and end up with billion-dollar blockbusters on their hands?
The Alzheimer’s Association estimates that the number of people with Alzheimer’s disease in the U.S. could more than triple by 2050, and sadly, the treatment options available to these patients are limited.